Balance deficits in long-term pediatric ALL survivors

Varedi, Mitra; Ness, Kirsten K.; McKenna, Raymond

doi:10.18632/oncotarget.25967

Cited by 3 publications

(3 citation statements)

References 7 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QoL may have given more insights into the clinical relevance of our study (Vetsch et al 2018 ; Corella Aznar et al 2019 ; Ness et al 2015 ; Goebel et al 2019 ), but was not measured due to already extensive testing. In future studies, large- and small-fiber neuropathy leading to motor function impairment could be tested by, e.g., 6-min walking test, and timed up-and-go test (Varedi et al 2018b ).…”

Section: Discussionmentioning

confidence: 99%

Long-term small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation

Ruscher

Lieber

Kühl

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose We aimed at describing for the first time peripheral small-fiber neurotoxicity and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation (SCT). Methods In a cross-sectional, retrospective, single-center study, we assessed 25 relapse-free long-term survivors (median age at SCT: 11 ± 4.9 years; median time between SCT and testing: 8.25 years, 19 males) using a reduced version of the pediatric-modified total neuropathy score for clinical assessment and Quantitative Sensory Testing (QST). Inclusion criteria: $$\ge$$ ≥ 6 years old at testing, $$\le$$ ≤ 18 years old at time of SCT, $$\ge$$ ≥ 1 year between SCT and testing. Results Nine patients (36%) had peripheral neuropathy as defined by the clinical red-pmTNS (≥ 4). The QST parameters mechanical pain sensitivity, mechanical detection threshold, thermal sensory limen, vibration detection threshold and pressure pain threshold were significantly abnormal in the survivor cohort (p < 0.0038). Except for one, all survivors showed at least one abnormal QST parameter. When using QST, signs of small and large fiber dysfunction were present in 22 (88%) and 17 (68%) survivors, respectively. More than half of all survivors were found to experience pathologic sensitization to pain. Conclusions and implications for cancer survivors Survivors of pediatric acute lymphoblastic leukemia after SCT are at high risk for long-term peripheral neuropathy with a dominating small-fiber and pain sensitization pattern.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation

Ruscher

Lieber

Kühl

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…At a similar follow‐up time of observation in a different cohort of childhood acute lymphoblastic leukemia survivors, neuropathy was still present in 63% . While Jain et al showed persistence of CIPN in more than one‐quarter of 80 patients nearly 2 years after treatment, Tay et al reported pathological neurophysiological results in 69% of survivors 4 years after treatment, and Varedi et al reported significant neuropathy presence compared to an equal control group more than 10 years after cancer diagnosis.…”

Section: Introductionmentioning

confidence: 89%

Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue

Cavaletti

Alberti

Lustberg

et al. 2019

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neurotoxicity (CIPN) is a potentially dose-limiting side effect of several commonly used cytotoxic chemotherapy agents. The main pharmacological classes that may cause CIPN include classical anticancer drugs, as well as the recently introduced immune checkpoint inhibitors and antibody drug conjugates.The absence of a complete knowledge of CIPN pathophysiology is only one of the several unsolved issues related to CIPN. Among some of the most relevant aspects of CIPN deserving further attention include the real number of patients exposed to the risk of CIPN, the long-term impact on cancer survivors' quality of life due to incomplete recovery from CIPN, the economic burden related to acute and chronic CIPN, and the different perspective and education of the healthcare specialists in charge of managing patients with CIPN. Overall, CIPN remains a very challenging area of research as there are still several unresolved issues to be addressed in the future. In this special issue, the multifaceted profile of CIPN will be presented, with particular emphasis on bolstering the need to develop more optimized outcome measures than the existing ones to accurately evaluate the extent of CIPN, but also to ascertain the differences in the incidence, risk factors, clinical phenotype, and management of CIPN, according to the most commonly used neurotoxic chemotherapy classes. Perspectives for future research to pursue in order to cover the gaps in knowledge in the CIPN field will also be discussed. K E Y W O R D Sadult, chemotherapy, children, economic costs, neurotoxicity

show abstract

“…Vincristine is used to treat childhood leukemia whereas vinblastine is used in combination with chemodrugs to treat breast and bladder cancers [12][13][14]. Although vincristine is successful for childhood leukemia often leads to neuropathy [14][15]. Thus identifying plant compounds with antileukemic properties and less toxicity will contribute to improve treatment outcome [11,[16][17]).…”

Section: Introductionmentioning

confidence: 99%

Hop-derived Xanthohumol Induces HL-60 Leukemia Cells Death

Pacurari

Brown

Rieland

2020

IJBcRR

View full text Add to dashboard Cite

Background: Acute promyelocytic leukemia (APL) affects both kids and adults, however it is more prevalent in younger population. Although APL has a favorable prognostic, patients that relapse often do not respond positively to additional chemotherapy. Therefore, there is a need to further identify ways to overcome these challenges. Hypothesis: In this study, we examined antileukemic effects of xanthohumol (XN), a prenylated flavonoid derived from hops (Humulus lupulus L), on human promyelocytic HL-60 cells. Materials and Methods: HL-60 cells were exposed to different concentrations of XN (μM) for 24 h. Cell viability, cell morphology, chromatin condensation, cPARP-1 level, and caspase-3 activation, and the expression of p21 WAF1/Cip1 were analyzed. Results: XN reduced HL-60 cell viability in a dose-dependent manner. XN induced a dosedependent morphological changes including cell shrinkage and blebbing, and significantly increased IJBCRR, 29(1): 61-72, 2020; Article no.IJBCRR.53095 62 the number of cells with condensed chromatin. XN significantly increased the level of cPARP-1, active caspase-3, and the expression of p21WAF/CIP mRNA. Conclusion: These data indicate that XN induces HL-60 cell death by regulating cell cycle progression and apoptosis. This study suggests that XN may have antileukemic preventive effects. Original Research Article

show abstract

Balance deficits in long-term pediatric ALL survivors

Cited by 3 publications

References 7 publications

Long-term small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation

Long-term small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia after stem cell transplantation

Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue

Hop-derived Xanthohumol Induces HL-60 Leukemia Cells Death

Contact Info

Product

Resources

About